Belzutifan versus everolimus in participants with previously treated advanced clear cell renal cell carcinoma: Randomized open-label phase III LITESPARK-005 study 
                                        
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            Safety and efficacy of two doses of belzutifan in patients with advanced RCC: Results of the randomized phase II LITESPARK-013 study 
                                        
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review 
                                        
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study 
                                        
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma 
                                        
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time 
                                        
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist’s Point of View 
                                        
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma 
                                        European Urology Oncology, October 2022
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma 
                                        
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups 
                                        European Urology Open Science, January 2023
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase 3 ZIRCON study 
                                        
                                        
                                        
                                                                     
                             
                                                    
                                
                                                                            Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups 
                                        
                                        
                                        
                                                                     
                             
                                             
                    
                             
         
     
 
    
		
		This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy. I agree Read More